Global High-Priority Regulatory Events — May 04, 2026

04-05-2026

LIC Housing Finance Ltd issued a notice for a Board Meeting scheduled on May 13, 2026, at 2:30 p.m. to consider and approve the Audited Financial Results (Standalone & Consolidated) for the fourth quarter and financial year ended March 31, 2026, and to recommend final dividend for FY 2025-2026, if any. The notice also mentions non-publication of unaudited Q4 and FY results, with the trading window closed for directors and designated employees from April 1, 2026, to May 15, 2026.

• ·Trading window closure period: 1st April 2026 to 15th May 2026 (both days inclusive)
• ·CIN: L65922MH1989PLC052277
• ·Company website: www.lichousing.com

04-05-2026

On May 4, 2026, the Hon’ble NCLAT pronounced its order in favor of Embassy Developments Limited, setting aside the NCLT order dated December 9, 2025, that had admitted the Corporate Insolvency Resolution Process (CIRP) against the Company. The CIRP has been quashed and closed, with all related directions terminated, relieving the Company from insolvency proceedings. The Company confirms it remains financially sound and operational in the normal course with no impact on business.

• ·Scrip Code: 532832; Symbol: EMBDL
• ·Previous intimation dated April 25, 2026
• ·Interim protection by NCLAT subsumed into final order
• ·Formal NCLAT order awaited and will be filed upon receipt

04-05-2026

The 23rd Committee of Creditors (COC) meeting of Bloom Dekor Limited in CIRP on April 21, 2026, approved the resolution plan submitted by Dr. Sunil Gupta & Mr. Karan Singh Wilkhoo dated April 23, 2026, declaring them the Successful Resolution Applicant and authorizing the Resolution Professional to proceed with filings under IBC. While COC members expressed inclination towards the resolution plan and deferred liquidation as a last resort pending NCLT approval, the company remains in insolvency with potential for liquidation if the plan fails. Various CIRP costs were ratified, including going concern expenses of Rs. 48,56,966.46.

• ·CS Tushar Dineshbhai Donda resigned w.e.f. November 19, 2024.
• ·Ratified change in designation of Mrs. Falguni Rajanbhai Shah from Chief Financial Officer to Chief Financial Officer & Additional Executive Director, approved in Board Meeting on March 21, 2026.
• ·Evaluation matrix for the Resolution Plan ratified.

04-05-2026

Prasanna Natarajan, Rajat Chakra Credit & Holdings Private Limited, Sipping Spirits Private Limited, and Saranga Investments & Consultancy Private Limited (collectively 'Acquirers'), along with PAC Rajalakshmi Natarajan, are making an open offer to acquire up to 70,00,000 equity shares (12.04% of the emerging voting share capital on a fully diluted basis) of Tejassvi Aaharam Limited at ₹10 per share, aggregating up to ₹7,00,00,000. The offer size is adjusted to the eligible public shareholding of 12.04% (instead of the standard 26% minimum under SEBI SAST Regulations) due to exclusions of deemed PACs from a preferential issue. This reminder advertisement was published on May 04, 2026, in Financial Express, Jansatta, Makkal Kural, and Pratahkal.

• ·Offer price equals face value of ₹10 per equity share
• ·Manager to the Offer: Saffron Capital Advisors Private Limited (SEBI Reg: INM000011211)
• ·Registrar to the Offer: Cameo Corporate Services Limited (SEBI Reg: INR000003753)
• ·Reminder Advertisement dated May 02, 2026, published May 04, 2026
• ·Eligible physical shareholders can request Letter of Offer (LOF) soft copy from registrar at priya@cameoindia.com or download from SEBI/BSE/Manager websites
• ·Tendering procedure detailed in LOF page 60

04-05-2026

04-05-2026

Kopran Limited notified BSE and NSE of newspaper advertisements published on May 02, 2026, in Free Press Journal and Navshakti, for NCLT-convened meetings of equity shareholders, secured creditors, and unsecured creditors of Kopran Laboratories Limited and Kopran Limited to approve the Scheme of Amalgamation (Merger by Absorption), pursuant to NCLT Mumbai Bench order dated April 09, 2026. Meetings are scheduled for June 3, 2026 via video conferencing, with remote e-voting from May 27 to June 2, 2026. However, the same newspaper includes DRT summons for debt recovery proceedings against both companies (OA/250/2025 for Rs. 2702797.17 and OA/249/2025 for Rs. 2559740.4) and a SARFAESI e-auction notice for Kopran Limited's flat with reserve price of Rs.47.10 Lakh.

• ·NCLT meetings via VC/OAVM: Equity Shareholders on June 3, 2026 at 10:00 AM IST; Secured Creditors at 11:30 AM IST.
• ·Remote e-voting period: May 27, 2026 9:00 AM IST to June 2, 2026 5:00 PM IST.
• ·DRT summons issued on March 6, 2026; defendants to appear before Registrar on May 8, 2026 at 10:30 AM.
• ·E-auction of Kopran Limited's flat (58.34 Sq. mtrs. built-up) on https://sarfaesi.auctiontiger.net; inspection May 29, 2026 3:00-4:00 PM.

04-05-2026

Apollo Hospitals Enterprise Limited announced that a Board of Directors meeting will be held on May 20, 2026, to approve the annual audited standalone and consolidated financial results for the three months and year ended March 31, 2026, and to recommend final dividend for FY 2025-2026, if any. The trading window remains closed for promoters, directors, and designated persons from April 1, 2026, until 48 hours after the financial results announcement, i.e., up to May 22, 2026. This intimation complies with Regulations 29, 42, and 50 of SEBI Listing Regulations and SEBI Prohibition of Insider Trading Regulations.

• ·Scrip Codes: BSE 508869, NSE APOLLOHOSP; ISIN INE437A01024
• ·Prior letter reference dated March 24, 2026
• ·Trading Window closure: April 1, 2026 to May 22, 2026

04-05-2026

GMR Solutions Inc., a Delaware-incorporated company in the EMS sector, filed Amendment No. 2 to its Form S-1 registration statement on May 4, 2026, for an initial public offering of 31,914,893 shares of Class A common stock priced between $22.00 and $25.00 per share, with listing on the NYSE under 'GMRS'. Funds affiliated with KKR Stockholder, Ares, and HPS expect to purchase $350,000,000 in private placement warrants concurrently. Post-offering and related transactions, KKR Stockholder will beneficially own approximately 75.5% of voting power, classifying the company as 'controlled' under NYSE rules; no financial performance metrics or declines are detailed in this preliminary prospectus.

• ·Registrant is a non-accelerated filer, not an emerging growth company.
• ·Underwriters have a 30-day option to purchase up to 4,787,233 additional shares for over-allotments.
• ·Principal executive offices: 4400 Hwy 121, Suite 700, Lewisville, TX 75056.
• ·Expected delivery of shares on or about [blank], 2026.

04-05-2026

Willow Lane Acquisition Corp. entered into a Business Combination Agreement on September 15, 2025, with Boost Run Holdings, LLC, Boost Run Inc. (Pubco), and related merger subs for a proposed SPAC business combination. Social media posts regarding the transaction were published by Boost Run, Willow Lane, and Willow Lane CEO B. Luke Weil on April 30, 2026. The filing emphasizes forward-looking statements about potential benefits alongside extensive risks, including deal termination, operational disruptions, and failure to complete the merger.

• ·Commission File No. 001-42400
• ·Filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934

04-05-2026

Odyssey Therapeutics, Inc. filed an S-1/A registration statement for an IPO offering 13,240,000 shares of common stock at a midpoint price of $17.00 per share, expecting approximately $205.2 million in net proceeds (or $236.6 million if underwriters' option for 1,986,000 additional shares is exercised in full), plus $23.3 million from a concurrent private placement of 1,470,588 shares to TPG Orazio II. The company intends to use proceeds to advance OD-001 through phase 2a combination and phase 2b monotherapy trials in ulcerative colitis, SLC15A4 program through IND-enabling and phase 1/2a trials, and other R&D. Financials reflect widening losses with net loss increasing 15% YoY to $148.6 million in 2025 from $129.3 million in 2024, driven by collaboration revenue declining 33% to $3.0 million, R&D expenses rising 12% to $126.6 million, and G&A up 38% to $37.5 million.

• ·1-for-9.7170 reverse stock split of voting common stock effected May 1, 2026
• ·Pro forma net loss per share $5.39 for year ended Dec 31, 2025
• ·4,631,713 shares of common stock issuable upon exercise of options at weighted average $4.94 per share as of Dec 31, 2025
• ·Nasdaq trading symbol proposed as 'ODTX'
• ·No anticipated cash dividends

04-05-2026

Mobia Medical, Inc. filed an S-1/A registration statement (No. 333-295160) on May 4, 2026, as part of its IPO process. The filing highlights a material weakness in internal controls over financial reporting, specifically in the review of inputs for net loss per share attributable to common stockholders, which led to revisions in the statement of operations for the year ended December 31, 2025. The company anticipates substantial increased legal, accounting, and compliance costs as a public company, no plans to pay dividends, and various anti-takeover provisions that could discourage changes in control.

• ·Material weakness remediation involves establishing controls over weighted-average shares outstanding and net loss per share calculation; not yet remediated.
• ·Subject to Section 404 of Sarbanes-Oxley Act requirements post-IPO, including formal assessment of internal controls starting with second annual 10-K.
• ·Anti-takeover provisions include classified board, blank check preferred stock, no stockholder action by written consent, and Section 203 of DGCL.
• ·No intention to pay cash dividends; returns limited to stock appreciation.
• ·Exclusive forum provisions designate Delaware Court of Chancery and U.S. federal courts for certain stockholder disputes.

04-05-2026

Lisata Therapeutics, Inc. entered into an Amendment and Waiver to its March 6, 2026 Merger Agreement with Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser), extending the tender offer commencement deadline from 26 to 59 business days due to Parent's delay, which highlights execution risks in the acquisition process. Parent will make non-refundable Interim Operating Payments totaling $1.1 million to cover Lisata's expenses during the delay, while Lisata waives related claims upon payment and offer commencement. The waiver period runs until May 29, 2026, with cooperation required to avoid further delays.

• ·Waiver Period: From May 3, 2026, until May 29, 2026
• ·Offer commencement extended to 59 Business Days after March 6, 2026
• ·Lisata may terminate waiver sections if Parent misses payments or commits material breach uncured within 2 Business Days
• ·Interim payments terminate upon Offer commencement or Merger Agreement termination

04-05-2026

Cerebras Systems Inc., an AI infrastructure company, filed Amendment No. 1 to its S-1 registration statement on May 4, 2026, for an initial public offering of 28,000,000 shares of Class A common stock at an anticipated price range of $115.00 to $125.00 per share, with listing on Nasdaq Global Select Market under symbol 'CBRS'. The offering includes an underwriters' over-allotment option for up to 4,200,000 additional shares, and post-IPO, outstanding Class B common stock will represent approximately 99.2% of voting power based on beneficial ownership as of March 31, 2026. The prospectus highlights the company's Wafer-Scale Engine 3 (WSE-3) with 4 trillion transistors, 900,000 cores, and claims of superiority over NVIDIA's B200 in scale and performance metrics.

• ·Company incorporated in Delaware, SIC code 3674, EIN 81-2256092.
• ·Principal executive offices: 1237 E. Arques Avenue, Sunnyvale, California 94085.
• ·Emerging growth company electing not to use extended transition period for new accounting standards.
• ·Legal counsel: Latham & Watkins LLP (Tad J. Freese, Sarah B. Axtell, Zuzanna V. Gruca); Davis Polk & Wardwell LLP (Alan F. Denenberg, Elizabeth W. LeBow).

04-05-2026

Liftoff Mobile, Inc. filed Amendment No. 1 to its S-1 registration statement on May 4, 2026, for an initial public offering of common stock on Nasdaq under the symbol LFTO, with shares offered at an expected price between $ and $ per share and underwritten by Goldman Sachs, Jefferies, and Morgan Stanley among others. Demand Side Customers grew 21% YoY from 728 in 2024 to 881 in 2025 but slightly declined to 878 in the three months ended March 31, 2026, while apps integrated with its SDK increased 29% YoY to 163,708 and further to 167,814. The platform connects to over 1.4 billion daily active users worldwide in Q1 2026, with pre-IPO majority control by Blackstone affiliates.

• ·Emerging growth company status elected, with non-accelerated filer.
• ·Pre-IPO majority voting control by Blackstone affiliates; potential 'controlled company' post-IPO.
• ·Principal executive offices: 900 Middlefield Road, Redwood City, California 94063.
• ·Intends -for-1 forward stock split prior to offering closing.

04-05-2026

TG-17, Inc. (OBAI), through its CEO Doron Kempel, filed Amendment No. 1 to the Certificate of Designations, Preferences and Rights of its Series C Convertible Preferred Stock, originally filed on September 16, 2025. The amendment, approved by the Board of Directors and requisite shareholders on May 4, 2026, adds a new Section 4(f) imposing a leak-out restriction: holders collectively cannot sell more than 10% of daily trading volume in conversion shares, unless sold at or above 115% of the prior day's closing sale price. All other provisions remain unchanged.

• ·Amendment executed pursuant to Nevada Revised Statutes Section 78.1955
• ·Original Certificate of Designations filed September 16, 2025

04-05-2026

National Vision Holdings, Inc. reported strong FY2025 financial performance with net revenue up 9.0% to $1,987.5 million, Adjusted Operating Income rising to $102.5 million from $65.5 million in FY2024 (Adjusted Operating Margin expanding 5.2 percentage points to 8.8% from 3.6%), and Adjusted Diluted EPS increasing to $0.80 from $0.52. Comparable store sales grew 5.9% (Adjusted 6.0%), while overall store count growth was flat at 0.8% to 1,250 stores. The proxy statement seeks stockholder approval for election of 11 director nominees, say-on-pay, and ratification of Deloitte & Touche LLP as auditors for 2026, ahead of the June 17, 2026 Annual Meeting.

• ·Annual Meeting scheduled for June 17, 2026 at 1:00 p.m. ET in Alpharetta, Georgia; record date April 20, 2026.
• ·Eleven director nominees proposed for election.
• ·Financial results reflect continuing operations; Legacy segment and majority of AC Lens treated as discontinued.

04-05-2026

Berkshire Hathaway's Q1 2026 total revenues increased 4.4% YoY to $93,675 million from $89,725 million, with sales and service revenues up 6.6% to $50,946 million, while insurance premiums grew modestly 0.9% to $22,005 million. Net earnings attributable to Berkshire shareholders more than doubled to $10,106 million from $4,603 million (+119.5%), boosted by smaller investment losses of $(1,605) million versus $(6,435) million and higher pre-tax operating earnings. However, equity securities decreased to $288,034 million from $297,778 million (-3.4%), operating cash flows fell slightly 4.3% to $10,438 million from $10,903 million, and interest/dividend income declined to $5,430 million from $5,632 million.

• ·Acquisitions of businesses used $9,690 million cash in Q1 2026.
• ·Purchases of equity securities $15,938 million and sales $24,087 million in Q1 2026.
• ·Treasury stock acquisitions $235 million in Q1 2026.
• ·Short-term investments in U.S. Treasury Bills increased to $339,261 million from $321,434 million.
• ·Net cash flows from investing activities improved to $(4,308) million from $(16,401) million YoY.

04-05-2026

Blueport Acquisition Ltd (Nasdaq: BPAC), a SPAC, and SingAuto Inc announced a definitive business combination agreement valued at $1.2 billion, under which SingAuto shareholders will receive approximately 120,000,000 ordinary shares of the resulting PubCo at $10.00 per share. The transaction involves a reincorporation merger followed by an acquisition merger, with closing expected by end of 2026 subject to regulatory approvals, shareholder votes, SEC review of the proxy/prospectus, and Nasdaq listing. No financial performance metrics or declines are disclosed, though forward-looking statements highlight execution risks including potential failure to close or realize benefits.

• ·SingAuto headquartered in Singapore, operates in Singapore and Middle East, focuses on CEVs for cold-chain logistics including frozen, chilled, fresh produce, and pharmaceuticals.
• ·Transaction unanimously approved by boards of both companies.
• ·Advisors: Loeb & Loeb LLP and Ogier (Blueport); Robinson & Cole LLP, ShookLin & Bok, Ogier (SingAuto).
• ·Form F-4 registration statement to be filed including proxy statement/prospectus.
• ·Filing references Blueport's Form 10-K for FY ended December 31, 2025, filed February 26, 2026.

04-05-2026

Collective Acquisition Corp. II priced its initial public offering at $220,000,000, consisting of 22,000,000 units at $10.00 per unit, with units to list on Nasdaq under 'CAIIU' starting April 29, 2026, and closing expected on April 30, 2026. Each unit includes one Class A ordinary share and one-half redeemable warrant exercisable at $11.50 per share. The blank check company, led by CEO Daniel Hoffman and Chairman Samuel Sayegh, focuses on mergers in sectors like defense technology and AI, with underwriters granted an option for 3,300,000 additional units.

• ·Units expected to separate for individual trading as 'CAII' (shares) and 'CAIIW' (warrants)
• ·Underwriter: Clear Street LLC (sole book-running manager)
• ·Legal counsel: Reed Smith LLP (Company), Walkers (Cayman) LLP (Cayman counsel), Morgan, Lewis & Bockius LLP (underwriters)
• ·Registration statement effective April 28, 2026
• ·45-day over-allotment option

04-05-2026

Flora Growth Corp. reported Q1 2026 revenue of $7,274 up 6% YoY from $6,866, with gross profit surging to $3,146 from $535 due to lower cost of sales. However, a $60,742 loss from changes in fair value of digital assets drove operating expenses to $65,799 and a $36,660 net loss from continuing operations, compared to $341 prior year, while total assets fell 65% QoQ to $45,190 from $130,235 and cash dropped to $1,978 from $5,596. Shareholders' equity declined to $36,797 from $70,552 amid significant share dilution to 2,430 outstanding from 1,046.

• ·Net cash used in operating activities $3,847 in Q1 2026 vs $2,661 prior year.
• ·No loss from discontinued operations in Q1 2026 vs $417 loss prior year.
• ·Long-term debt reduced to $38 from $50,767 QoQ.
• ·Restricted digital assets $0 vs $49,000 QoQ.

04-05-2026

Immersion Corp reported total revenues of $518,488 thousand for the three months ended January 31, 2026, up 9.9% YoY to $518.5M, driven by Barnes & Noble Education's product and other sales growth of 12.4% to $471,825 thousand; however, Immersion's core royalty and license revenue declined 59.7% to $3,396 thousand, rental income was flat at +0.2%, and the company posted a net loss attributable to stockholders of $10,266 thousand versus $24,061 thousand profit last year. For the nine months ended January 31, 2026, revenues increased 14.9% YoY to $1,460,694 thousand with BNED strength, but Immersion royalties plunged 81.7% to $13,028 thousand, resulting in net income attributable to stockholders of just $795 thousand compared to $81,942 thousand prior year. Total assets expanded 29.9% to $1,432,720 thousand as of January 31, 2026 from $1,102,273 thousand at April 30, 2025, reflecting BNED consolidation.

• ·Previously-issued financial statements restated (Note 3)
• ·Business combination discussed (Note 4)
• ·Noncontrolling interest in consolidated subsidiaries: $266,619 thousand as of Jan 31, 2026
• ·Dividends declared: $2,516 thousand in Q3 FY2026
• ·Stock repurchases: 1,700 shares for $10 thousand in Q3 FY2026
• ·Impairment loss: $1,018 thousand in Q3 FY2026
• ·Filing includes disclosures on restatement, business combination, participation interest purchase agreement (Note 11), and subsequent events (Note 20)

04-05-2026

For the three months ended March 31, 2026, total operating revenue increased 4.8% YoY to $6,672 million, with energy revenue up 5.5% to $5,810 million while real estate revenue was essentially flat at $862 million. Operating income rose 5.4% YoY to $1,458 million; however, net income attributable to BHE shareholders declined 6.2% to $1,114 million due to higher interest expense and reduced other income. Total assets expanded 2.5% QoQ to $152,029 million as of March 31, 2026, supported by cash surging 148% to $4,203 million, though property, plant and equipment net decreased 0.7% to $111,566 million.

• ·Wildfires liabilities (current portion) decreased QoQ to $160M from $734M.
• ·Short-term debt decreased QoQ to $1,005M from $1,997M.
• ·Interest expense increased 8.7% YoY to $746M.
• ·Subsidiary senior debt increased to $45,500M from $42,759M as of December 31, 2025.

04-05-2026

Illumina reported Q1 2026 total revenue of $1,091M, up 4.8% YoY from $1,041M, driven by 4.2% growth in product revenue to $917M and 8.1% in services to $174M, while gross profit rose 5.6% to $721M and operating income surged 27.4% to $209M due to modestly lower operating expenses. However, other expense net swung to a $52M loss from $18M income, causing pre-tax income to decline 13.7% to $157M, with net income up slightly 2.3% to $134M; cash and equivalents fell $329M QoQ to $1,089M amid $415M paid for acquisitions and $242M share repurchases.

• ·Acquired net assets include $171M goodwill and $186M intangible assets.
• ·Net cash provided by operating activities increased 20.4% YoY to $289M.
• ·Term debt steady at $1,990M total (current $499M + long-term $1,490M).

04-05-2026

Aura Biosciences appointed Natalie Holles as Chief Executive Officer, President, and Board member effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D., who stepped down from her roles. The Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma has enrolled 86 patients as of May 4, 2026, with over 25 additional patients scheduled or identified for screening through May 2026, on track for enrollment completion by mid-2026 and topline data in the second half of 2027. No declines or flat performance metrics were reported.

• ·CoMpass trial is under Special Protocol Assessment agreement with FDA and has Orphan Drug Designation from FDA and EMA, plus Fast Track designation from FDA.
• ·Natalie Holles has over 25 years of experience, including prior CEO roles at Third Harmonic Bio and Audentes Therapeutics.

04-05-2026

On May 3, 2026, Modiv Industrial, Inc. and its Operating Partnership entered into a Merger Agreement with Global Net Lease, Inc. and affiliates, providing for Modiv to merge into a GNL subsidiary, with holders of Modiv Class C common stock receiving 1.975 shares of GNL common stock per share and holders of 7.375% Series A Preferred Stock receiving $25.00 per share in cash plus accrued dividends. The transaction, approved by both boards, requires Modiv shareholder approval, NYSE listing of GNL shares, tax opinions, and absence of material adverse effects, with an outside date of February 3, 2027. Termination fees of $10M or $15M apply in specified scenarios, including superior proposals or breaches.

• ·Modiv Class C common stock and preferred stock to be delisted from NYSE and deregistered under Exchange Act post-merger.
• ·Class X Units in Operating Partnership to vest into Class C Units immediately prior to OpCo Merger, then convert to 1.975 GNL OP Units.
• ·Company must convene special stockholder meeting for majority approval of Company Merger.
• ·GNL to file Form S-4 Registration Statement including proxy statement with Company Board recommendation to vote in favor.

04-05-2026

On May 3, 2026, Global Net Lease, Inc. (GNL) entered into a definitive Merger Agreement with Modiv Industrial, Inc. and its operating partnership, under which Modiv will merge into GNL's merger sub, with Modiv common stockholders receiving 1.975 shares of GNL common stock per share and Modiv preferred stockholders receiving $25.00 in cash plus accrued dividends per share. The transaction also involves an OP merger with equivalent 1.975 exchange ratio for OP units, subject to stockholder approval, NYSE listing, tax opinions, and other customary closing conditions, with an outside date of February 3, 2027. Termination fees of $10,000,000 or $15,000,000 may apply under specified circumstances.

• ·Unanimous board approvals from both GNL and Modiv.
• ·Modiv stockholder meeting required for majority approval of the merger.
• ·GNL to file Form S-4 Registration Statement including Proxy Statement/Prospectus.
• ·Tax opinions required confirming REIT status and Section 368(a) reorganization treatment.
• ·Transition services agreements with Aaron Halfacre and John Raney post-closing.
• ·GNL OpCo Partnership Agreement Amendment to include OP Unit Call Right.

04-05-2026

Apimeds Pharmaceuticals US, Inc. entered into a Settlement Agreement on April 24, 2026, resolving disputes from a prior Merger Agreement, under which Lokahi Therapeutics retains the Apitox program and provides a $4M working capital contribution plus forgiveness of a $750k advance, while the Company forms Newco and distributes 51% of Lokahi stock. Concurrently, a Forbearance Agreement with Alto Opportunity Master Fund grants temporary relief from defaults on an $11M convertible note until June 30, 2026, subject to strict conditions including timely 10-K filing and NYSE compliance. However, the Side Letter allows potential merger unwind if the 10-K is delayed past April 30, 2026 or receives a qualified audit opinion, and board changes introduce interim uncertainty with Mr. Koo's resignation and planned transition to new directors.

• ·Irrevocable proxy granted by Inscobee Parties to Dr. Vin Menon and Captain Sandeep Singh Yadav until the later of NYSE approval, Preferred Stock Conversion, NYSE denial, or July 30, 2026.
• ·Newco to receive 10% of net financing proceeds from Company's existing investor arrangement; spin-off expected within 12 months, extendable by another 12 months.
• ·Forbearance Conditions include 10-K filing by April 30, 2026, registration statement effective by June 30, 2026, 1-for-10 reverse stock split, and NYSE compliance by June 30, 2026.
• ·Stockholder Consents purporting to remove directors declared void; board temporarily reduces to three members during Interim Period until 10-K filing.

04-05-2026

George Furlan resigned as Director and Interim Chief Executive Officer effective April 24, 2026, with the resignation accepted by the Board on May 1, 2026, and no disagreements on company operations, policies, or practices. The Board, now consisting of Eric Bruns (Chairman) and Dionne Harvey Pendleton, designated Serge Knazev (President and COO since January 1, 2026) as Acting Principal Executive Officer effective May 1, 2026, pending searches for a permanent CEO and new director. Compensation owed to Mr. Furlan for periods ended December 31, 2025, and March 31, 2026, is under review, with no separation agreement entered as of the filing date.

• ·Resignation informed telephonically on April 24, 2026; written notice received April 29, 2026.
• ·Company will amend this 8-K within four business days if material separation terms are determined for Mr. Furlan.

04-05-2026

Arman Financial Services Limited announced participation in the Second 100-days Campaign 'Saksham Niveshak' from April 01, 2026 to July 09, 2026, following IEPFA and MCA intimation dated March 27, 2026, to urge shareholders to update KYC details (PAN, nomination, contact, bank details) and claim unpaid/unclaimed dividends, particularly for FY 2018-19, before transfer to IEPF. The company has proactively sent reminder letters and directs shareholders to submit forms ISR-1 to ISR-4, SH-13, and SH-14 to RTA Bigshare Services Private Limited. Earlier dividends for FY 2017-18 and prior have already been transferred to IEPF.

• ·RTA contact: No 303, Sun Square Complex, Near Chakradhari Society Bus Stop, Girish Cold Drinks Cross Road, C.G. Road, Navrangpura, Ahmedabad-380009; Email: bssahd@bigshareonline.com; Phone: +91 079 4919 6459
• ·Forms downloadable from https://www.bigshareonline.com/resources-sebi_circular.aspx or https://armanindia.com/OtherReports.aspx?Page=Other-Disclousers
• ·Assistance email: secretarial@armanindia.com
• ·Company website: www.armanindia.com

04-05-2026

CNA Financial Corp's Q1 2026 total revenues rose 1.4% YoY to $3,677M from $3,627M, supported by net earned premiums growth of 2.9% to $2,701M and net investment income up 1.0% to $610M; however, non-insurance warranty revenue declined 5.8% to $374M. Net income fell sharply 23.0% YoY to $211M from $274M due to higher insurance claims and benefits of $2,175M (up 7.4%), resulting in basic EPS of $0.78 versus $1.01. Comprehensive loss totaled $40M, contrasting with $480M comprehensive income in Q1 2025, driven by net unrealized investment losses of $432M.

• ·Net cash flows from operating activities declined to $393M from $638M YoY.
• ·Total investments decreased to $49,502M as of March 31, 2026 from $50,447M at Dec 31, 2025.
• ·Dividends paid to common stockholders $678M ($2.48 per share) in Q1 2026 vs $673M ($2.46 per share) in Q1 2025.
• ·Fixed maturity securities at fair value $43,230M (Mar 31, 2026) vs $43,402M (Dec 31, 2025).

04-05-2026

Fervo Energy Company filed an S-1/A amendment for its initial public offering of 55,555,555 shares of Class A common stock, priced between $21.00 and $24.00 per share, with plans to list on NASDAQ under the symbol 'FRVO'. Cornerstone Investors have indicated interest in purchasing up to $350 million in shares. Post-IPO, CEO Tim Latimer and CTO Jack Norbeck will beneficially own 2.89% of outstanding capital stock but control 54.37% of voting power via Class B shares.

• ·Underwriters granted 30-day option for additional 8,333,333 shares.
• ·Emerging growth company and smaller reporting company status elected.
• ·Principal executive offices at 811 Main Street, Suite 1700, Houston, TX 77002.

04-05-2026

Imunon, Inc. (IMNN) filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders on June 16, 2026, at 10:00 a.m. ET virtually, with a record date of April 17, 2026, and 3,983,342 shares of common stock outstanding. Shareholders will vote on Proposal 1 (election of Class I directors by plurality), Proposal 2 (ratification of WithumSmith+Brown PC as independent auditors for the year ending December 31, 2026), Proposal 3 (non-binding advisory approval of 2025 Named Executive Officer compensation), and Proposal 4 (amendment to the 2018 Stock Incentive Plan). No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Voting methods: internet at www.proxyvote.com, phone, proxy card, or live webcast at www.virtualshareholdermeeting.com/IMNN2026 using 16-digit control number
• ·Broker non-votes expected only on Proposal 2 (routine); non-routine for Proposals 1, 3, 4
• ·2025 Annual Report on Form 10-K available at www.sec.gov or www.imunon.com

04-05-2026

Cabaletta Bio, Inc. (CABA) announced the pricing of an underwritten public offering of 51,725,000 shares of common stock at $2.90 per share, expected to generate approximately $150 million in aggregate gross proceeds before expenses. The offering includes participation from Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, Eli Lilly and Company, and other investors, with TD Cowen, Guggenheim Securities, and Cantor as joint book-running managers. The offering is expected to close on or about May 5, 2026, subject to customary conditions.

• ·Offering priced at $2.90 per share, representing the at-the-market price under Nasdaq rules.
• ·All shares sold by Cabaletta; pursuant to shelf registration on Form S-3-ASR (File No. 333-278126), effective March 31, 2025.
• ·Headquarters and labs located in Philadelphia, PA.

04-05-2026

Zenrock Chemicals Private Limited (Acquirer) along with PACs India Special Assets Fund III, ISAF III Onshore Fund, and Special Situation India Fund has published the Post Offer Advertisement dated May 02, 2026, on May 04, 2026, in Financial Express (English All Edition), Jansatta (Hindi All Edition), and Navshakti (Marathi Mumbai Edition) to notify public shareholders of Indo Borax & Chemicals Limited of the open offer completion under SEBI (SAST) Regulations. The filing to BSE and NSE encloses the advertisement from Financial Express. IIFL Capital Services Limited serves as the manager, with designated contact persons for clarifications.

• ·Prior submissions: Public Announcement (PA) on December 15, 2025; Detailed Public Statement (DPS) on December 22, 2025; Draft Letter of Offer (DLOF) on December 30, 2025; Letter of Offer (LOF) on April 02, 2026; Offer Opening Public Announcement cum Corrigendum on April 09, 2026.
• ·Publication in compliance with Regulation 18(12) of SEBI (SAST) Regulations.

04-05-2026

Krystal Biotech reported Q1 2026 product revenue of $116,357 thousand, up 32% YoY from $88,183 thousand, fueled by initial contributions from Europe ($20,677 thousand) and Japan ($8,191 thousand), while US revenue was nearly flat, declining 1% YoY to $87,489 thousand from $88,183 thousand. Net income increased 57% YoY to $55,932 thousand, with diluted EPS rising to $1.83 from $1.20, and operating cash flow more than doubled to $80,382 thousand from $30,969 thousand. Total assets grew 5% QoQ to $1,396,967 thousand, though short-term investments declined 3% QoQ to $322,092 thousand and comprehensive income fell due to unrealized losses.

• ·Customer A represented 62% of accounts receivable as of March 31, 2026 (down from 66% at December 31, 2025); Customer B 13% (down from 14%).
• ·Stock-based compensation expense was $14,455 thousand in Q1 2026.
• ·Net cash used in investing activities was $63,583 thousand in Q1 2026.
• ·Weighted-average diluted shares outstanding: 30,507 thousand in Q1 2026 vs 29,871 thousand in Q1 2025.

04-05-2026

CNS Pharmaceuticals, Inc. entered into a private placement with institutional investors for 650,000 shares of common stock at $2.30 per share and pre-funded warrants to purchase 9,143,479 shares at $2.299 per warrant, expecting gross proceeds of approximately $22.5 million before fees for acquiring new assets and general corporate purposes. Jerzy (George) Gumulka resigned from the Board without any disagreements, and Michal Fisher was appointed as an independent director with extensive life sciences experience. The offering includes a 120-day lock-up on equity sales and restrictions on variable rate transactions for one year.

• ·Closing of offering expected on May 5, 2026, subject to customary conditions.
• ·Registration statement for resale of shares to be filed within 15 days of closing, effective within 60 days (or 90 days if reviewed).
• ·No equity sales or variable rate transactions for 120 days post-registration effectiveness (with exceptions), and no variable rate transactions for one year post-closing.

04-05-2026

Apellis Pharmaceuticals, Inc. amended and restated its Executive Separation Benefits and Retention Plan (A&R Separation Benefits Plan) effective upon the closing of its merger with Biogen Inc., as per the Merger Agreement. The amendments accelerate vesting of Converted Options and Converted RSU Awards for participants, including named executive officers, upon termination without cause or resignation for good reason, and modify the 'Good Reason' definition for C-Level Officers to not exclude changes due to becoming a subsidiary. No financial impacts or performance metrics are disclosed in the filing.

• ·Amendments apply to all participants including named executive officers.
• ·Plan effective on Closing Date of Merger Agreement.
• ·Date of earliest event: April 28, 2026; Filing Date: May 4, 2026.

04-05-2026

GameStop Corp. submitted a non-binding proposal on May 3, 2026, to acquire all outstanding shares of eBay Inc. at $125.00 per share (50% cash, 50% stock), representing a 46% premium to eBay's unaffected closing price on February 4, 2026, and an aggregate equity value of approximately $55.5 billion. The proposal highlights projected $2 billion in annualized cost savings for eBay and synergies from GameStop's ~1,600 US locations, but is subject to customary closing conditions including shareholder and antitrust approvals with no guarantee of a binding agreement. GameStop has accumulated a 5% economic stake in eBay and holds ~$9.4 billion in cash and liquid investments as of January 31, 2026.

• ·eBay spent $2.4B on Sales & Marketing in fiscal 2025.
• ·GameStop to file Schedule 13D and HSR notification on May 4, 2026.
• ·Transaction funding from GameStop's cash, liquid investments, and third-party equity/debt financing.

04-05-2026

Calisa Acquisition Corp received a notice from Nasdaq on April 30, 2026, stating non-compliance with Listing Rule 5450(a)(2), which requires at least 400 Total Holders of ordinary shares for continued listing. The company must submit a compliance plan by June 15, 2026, with potential extension up to 180 days if accepted, and intends to do so. This poses a risk of delisting if unresolved.

• ·Notice received: April 30, 2026
• ·Compliance plan due: no later than June 15, 2026
• ·Potential extension: up to 180 calendar days from April 30, 2026, if plan accepted
• ·Appeal opportunity: Nasdaq Hearings Panel if plan rejected

04-05-2026

Meghmani Organics Limited, the Transferee Company, is convening an equity shareholders' meeting on June 6, 2026, at 02:00 p.m. IST via video conferencing/other audio-visual means to consider and approve the Scheme of Amalgamation with Transferor Companies Kilburn Chemicals Limited and Meghmani Crop Nutrition Limited, pursuant to NCLT Ahmedabad Bench orders dated April 20, 2026 (amended April 30, 2026). The shareholding pattern for Meghmani Organics remains unchanged pre- and post-scheme at 48.95% for Promoter/Promoter Group and 51.05% for public shareholders, while shares of both Transferor Companies (100% promoter-held) will be cancelled upon scheme effectiveness.

• ·NCLT Application: CA(CAA)/23(AHM)2026
• ·Cut-off date for notice eligibility: March 27, 2026
• ·Cut-off date for e-voting eligibility: May 30, 2026
• ·Remote e-voting period: June 3, 2026 (9:00 a.m. IST) to June 5, 2026 (5:00 p.m. IST)
• ·Electronic Voting Sequence Number (EVSN): 260227
• ·CIN of Meghmani Organics Limited: L24299GJ2019PLC110321
• ·Symbol: MOL (NSE), Scrip Code: 543331 (BSE)

04-05-2026

EagleRock Land, LLC, a Permian Basin land management company, filed an S-1/A amendment for its IPO, highlighting ownership/control of approximately 236,000 acres plus interest in up to 70,000 acres, with acreage expanding from 122,132 acres (2024) to 193,875 acres (2025). Revenues surged 308% YoY from $17,701 thousand in 2024 to $72,173 thousand in 2025, driven by resource sales, surface use royalties, and infrastructure royalties, alongside Adjusted EBITDA growth from $7,350 thousand to $35,533 thousand; however, net losses widened from $(1,075) thousand to $(73,071) thousand. Pro forma as adjusted 2025 figures show revenues of $141,438 thousand and net income of $2,409 thousand.

• ·Produced water infrastructure capable of handling up to 400 MBbls/d under long-term contracts.
• ·Commercial water wells and infrastructure allow production and sale in excess of 200 MMBbls of water per year.
• ·Access to up to 3 MMBbls/d of produced water for treatment and recycling.
• ·First AGI well contracted, projected to commence revenue activities within next two years.
• ·Capital expenditures: $(1,482) thousand in 2024 and $(5,252) thousand in 2025.
• ·Free Cash Flow: $5,868 thousand in 2024 and $30,281 thousand in 2025.

04-05-2026

For Q1 2026, Boardwalk Pipeline Partners reported total operating revenues of $623.1M, up 0.7% YoY from $618.6M, with transportation revenues rising 5.4% to $416.4M and storage up 17.6% to $62.0M, but product sales declined sharply 18.7% to $124.1M. Net income grew 2.5% YoY to $211.7M, while operating income increased 1.5% to $248.2M. However, QoQ total assets fell 3.9% to $10,109.2M from $10,513.4M, cash equivalents dropped 34.0% to $329.6M amid $550.0M debt repayment, and capital expenditures rose significantly to $143.6M.

• ·Operating cash flow increased slightly 0.8% YoY to $245.9M from $243.9M.
• ·Net cash used in financing activities was $625.2M in Q1 2026 vs $74.4M in Q1 2025, driven by debt repayment.
• ·Firm service revenues from contracts with customers: Natural Gas $405.9M, Natural Gas Liquids $134.3M, Total $540.2M.

04-05-2026

Jagsonpal Pharmaceuticals reported modest FY26 revenue growth of 7% to ₹287 Cr after two quarters of sluggish performance, but achieved strong profit growth of 19% to ₹45 Cr before exceptional items from new labor code, with Q4 showing recovery via 10% YoY revenue increase to ₹64 Cr and 14.2% growth outperforming IPM's 10.5%. EBITDA for FY26 was ₹61 Cr at 21% margin, with cash position over ₹190 Cr enabling a ₹40 Cr buyback and 200% dividend for total shareholder returns of over ₹66 Cr. Management expressed confidence in accelerating growth to 1.5x IPM via enhanced MR productivity, while some mature brands saw moderation offset by Gynaecology and Dermatology gains.

• ·Net working capital cycle at 11 days.
• ·Top 10 brands constitute 58-60% of sales, with 9/10 ranked top 5 in categories.
• ·ROE to improve from 16% to 18%, ROCE from 22% to 26% post-buyback.
• ·Guidance for FY27: 1.5x IPM growth.
• ·Buyback record date May 04, 2026; no promoter participation.

04-05-2026

SunOpta Inc. (Nasdaq: STKL, TSX: SOY) completed its acquisition by an affiliate of Refresco Holding B.V. for US$6.50 per Common Share in cash on May 1, 2026, following shareholder approval on April 16, 2026, and a final court order on April 22, 2026. SunOpta's shares will be delisted from the TSX and Nasdaq, it will cease to be a reporting issuer under Canadian securities laws, and deregister under U.S. securities laws. While the transaction provides immediate cash to shareholders, forward-looking statements highlight risks including potential business disruptions, employee retention issues, litigation, and operating costs exceeding expectations.

• ·Registered shareholders must submit letter of transmittal and share certificates/DRS advices to TSX Trust Company to receive Consideration.
• ·SunOpta has over 50 years of expertise in customized supply chain solutions for beverages, broths, and better-for-you snacks.